The abstract is read at the publisher; the summary is JClub's.
dLbCas12a-based CRISPRi/a in Yarrowia lipolytica yields more consistent, stronger late-stage depletion than denAsCas12a in a pooled library of 752 crRNAs.
- Why it matters: Cas12a CRISPRi/a is less developed than Cas9 in Y. lipolytica, limiting genome-scale pooled screening that could better access promoter regions and multiplex regulation.
- What they did: The study benchmarked dLbCas12a versus denAsCas12a in single-gene assays and pooled CRISPRi targeting nine essential or conditionally essential genes using 752 crRNAs, then mapped crRNA features and tested dHyperLbCas12a.
- The result: dLbCas12a enabled enrichment-based CRISPRi and CRISPRa screens and identified targeting rules: effective intervals from approximately -260 to +50 bp, 18-nt crRNAs outperforming 20-, 23-, and 25-nt variants, and dHyperLbCas12a producing substantially stronger phenotypes than dLbCas12a.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.